ICU Medical Director Reports 1,200-Share Purchase on 08/27/2025

Rhea-AI Filing Summary

David C. Greenberg, a director of ICU Medical, Inc. (ICUI), reported open-market purchases on 08/27/2025. The Form 4 shows two non-derivative purchases: 602 shares at a weighted-average price of $126.1428, bringing his direct beneficial ownership to 7,362 shares, and 598 shares at a weighted-average price of $126.6895, bringing his direct beneficial ownership to 7,960 shares. The filing also discloses 500 shares held indirectly by a trust. The purchases were executed in multiple transactions within the disclosed price ranges; the filer offers to provide detailed per-transaction pricing on request.

Positive

• Director purchase disclosed: David C. Greenberg bought 1,200 shares on 08/27/2025, signaling insider buying.
• Transparent reporting: Weighted-average prices and price ranges are disclosed with a commitment to provide per-trade details on request.

Negative

• None.

Insights

Financial Analyst

TL;DR: A company director made modest open-market buys totaling 1,200 shares at ~ $126–127, increasing direct ownership.

These purchases represent routine insider buying by a director and may signal confidence, though the sizes (602 and 598 shares) are small relative to typical institutional levels. The Form 4 provides weighted-average prices and discloses that trades occurred across multiple executions. No options or derivative transactions were reported. Absent additional context on total share count or recent trading patterns, this is a limited, liquidity-scale insider purchase rather than a transformative ownership change.

Corporate Governance Expert

TL;DR: Reporting is compliant and transparent; multiple-execution prices are disclosed with offer to provide detail.

The filing properly identifies the reporting person as a director, shows individual filing status, and includes an attorney-in-fact signature. The explanatory footnotes transparently state that reported prices are weighted averages across ranges and offer to furnish per-trade details upon request, which supports governance transparency. No departures from normal Section 16 reporting practices are evident.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Greenberg David C.

(Last) (First) (Middle)

951 CALLE AMANECER

(Street)

SAN CLEMENTE CA 92673

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		P		602	A	$126.1428(1)	7,362	D
Common Stock	08/27/2025		P		598	A	$126.6895(2)	7,960	D
Common Stock								500	I	by Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $125.52 to $126.48, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

2. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $126.55 to $127.14, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

	By: Paula Darbyshire, Attorney-in-Fact For: David C. Greenberg	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider trades did David C. Greenberg report for ICUI on 08/27/2025?

He reported two open-market purchases totaling 1,200 shares (602 and 598 shares) on 08/27/2025.

What prices did the Form 4 report for the ICUI purchases?

The Form 4 reports weighted-average prices of $126.1428 and $126.6895, with per-trade ranges disclosed in footnotes.

How many ICUI shares does David C. Greenberg beneficially own after these transactions?

The filing shows 7,362 shares and 7,960 shares reported following each respective purchase and 500 shares held indirectly by a trust.

Was the Form 4 filed individually or on behalf of multiple reporting persons?

The Form 4 was filed by one reporting person (individual filing checked).

Who signed the Form 4 on behalf of David C. Greenberg?

The Form 4 was signed by Paula Darbyshire, Attorney-in-Fact for David C. Greenberg on 08/27/2025.